Researchers at Toulon General Hospital, France, have announced the first inclusion in a new HAART intensification trial aimed at analyzing residual HIV disease and reservoirs. Named ‘IntensVih’ in French (ClinicalTrials.gov Identifier: NCT00935480), this trial will study the ‘Impact of Therapy Intensification by an Integrase Inhibitor +/- a CCR5 Inhibitor on the Lymphoid Reservoir for HIV-1 in Chronically Infected Patients’
Toulon, France, December 08, 2010 — The IntensHiv trial will test durable intensification both at the blood and tissue levels. It will also combine in the intensification cocktail two new antiretrovirals acting differently: Raltegravir, an HIV integrase inhibitor, and Maraviroc, a CCR5 (coreceptor) inhibitor.
Thirty six HIV-infected patients on effective HAART including a boosted PI will be randomized within the next 12 months to either the intensified regimen or the control arm. Intensified patients will receive raltegravir for 12 months in addition to their usual regimen, plus Maraviroc if CCR5 HIV tropism is found on proviral DNA by genotyping. The evolution of the HIV reservoir will be followed in these patients both in plasma, peripheral mononuclear cells and gut biopsies.
This study will provide data on the nature and origin of persistent HIV RNA on effective therapy, ont the role of tissue reservoirs, on immune changes with Raltegravir/Maraviroc combination and will establish if 2 RTI + boosted PI + Raltegravir + Maraviroc is the correct background regimen to use in future eradication trials.
Toulon General Hospital is part of the “Researcher Community on HIV Reservoirs and Eradication Strategies” recently founded to help find a cure against HIV: http://www.hiv-reservoir.net
Press Release Distribution By PressReleasePoint
Contact:
Alain Lafeuillade
CHITS
1208 avenue Colonel Picot
Toulon, France 83100
33494616340
[email protected]
http://hiv-reservoir.net/index.php/Latest-News-on-HIV-Reservoirs-Eradication/intens-hiv.html
